@article{a5ad75ce0ada48fe9f61eaa8778b2ad7,
title = "Antibodies: what makes us stronger",
abstract = "Neutralizing antibodies are the basis of almost all approved prophylactic vaccines and the foundation of effective protection from pathogens, including the recently emerging SARS Coronavirus 2 (SARS-CoV-2). However, the contribution of antibodies to protection and to the course of the disease during first-time exposure to a pathogen is unknown. We analyzed the antibodies and B cell responses in severe and mild COVID-19 patients. Despite our primary assumption that high antibody titers contribute to a mild disease, we found that severe COVID-19 illness, and not mild infection, correlates with strong anti-viral antibody and memory B cell responses. This phenomenon was also demonstrated for anti-Mycobacterium tuberculosis inhibiting antibodies that we recently isolated from an actively infected Tuberculosis-sick donor. This correlation between disease severity and antibody responses can be explained by the fact that high viral loads drive B cell stimulation and generation of high-affinity antibodies that will be protective upon future encounter with the particular pathogen.",
keywords = "B cells, SARS-CoV-2, neutralizing antibodies, tuberculosis",
author = "Freund, {Natalia T.}",
note = "Publisher Copyright: {\textcopyright} 2021 Taylor & Francis Group, LLC.",
year = "2021",
doi = "10.1080/21645515.2021.1929034",
language = "אנגלית",
volume = "17",
pages = "3551--3553",
journal = "Human Vaccines and Immunotherapeutics",
issn = "2164-5515",
publisher = "Landes Bioscience",
number = "10",
}